Here's a segment breakdown with timestamps:[0:58 – 1:43] Introduction &amp; Career Background [1:44 – 7:04] Regulation &amp; the "Daughter Test" [7:05 – 13:15] From Tech to Biotech: The Pivot [13:16 – 21:35] AI at Retro &amp; the OpenAI Partnership [21:36 – 25:20] The 10-Year Lifespan Mission Explained [25:21 – 33:20] Lead Program: Alzheimer's &amp; Autophagy [33:21 – 40:00] Broader Pipeline &amp; Company Philosophy [40:01 – 45:50] Cell Replacement vs. Cell Rejuvenation [45:51 – 51:55] AI-Designed Transcription Factors &amp; Partial Reprogramming [51:56 – 54:03] On Biohackers &amp; the DTC Longevity Industry [54:04 – 56:02] "Whose Lives Are We Extending?" &amp; Closing Thoughts &nbsp;

In this episode of the Nucleate Podcast, Joe Betts-LaCroix, co-founder of Retro Biosciences, traces his path from Silicon Valley hardware startups to longevity biotech, explaining that a liquidity event from his first company prompted him to reflect on the limited real-world impact of most tech products compared to medicine, which almost always meaningfully helps people. He describes Retro's approach to navigating biotech regulation through a "daughter test" – asking whether a given regulatory requirement is one he'd genuinely want applied if it were his own family member's treatment on the line. He then explains why the company has set an ambitious but achievable mission of extending healthy human lifespan by 10 years, framing it as a "right-sized" goal for a venture-backed startup.

The conversation then dives into Retro's science and pipeline, including a notable collaboration with one of their major investors, OpenAI, to retrain a large language model on amino acid sequences, which unexpectedly produced improved Yamanaka factors used in cellular reprogramming — work now feeding into Retro's FDA filings. Joe discusses the company's twin strategies of replacing aged cells entirely versus partially reprogramming cells in place to rejuvenate them without erasing cell identity, and explains why their lead Alzheimer's program targets intracellular autophagy dysfunction rather than the more traditional extracellular amyloid-beta approach, despite the field's history of failed drugs. He closes with reflections on the broader longevity industry — expressing sympathy for experimentation but skepticism toward supplement vendors who oversell single mechanisms as cure-alls.


AI, Amino Acids, and Aging: Inside Retro Biosciences | Joe Betts-Lacroix

Description